These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

253 related items for PubMed ID: 31519804

  • 21. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies.
    Béhé M, Behr TM.
    Biopolymers; 2002; 66(6):399-418. PubMed ID: 12658727
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Comparison of three radiolabelled peptide analogues for CCK-2 receptor scintigraphy in medullary thyroid carcinoma.
    Fröberg AC, de Jong M, Nock BA, Breeman WA, Erion JL, Maina T, Verdijsseldonck M, de Herder WW, van der Lugt A, Kooij PP, Krenning EP.
    Eur J Nucl Med Mol Imaging; 2009 Aug; 36(8):1265-72. PubMed ID: 19266197
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Dosimetry and pharmacokinetics of [177Lu]Lu-satoreotide tetraxetan in patients with progressive neuroendocrine tumours.
    Schürrle SB, Eberlein U, Ansquer C, Beauregard JM, Durand-Gasselin L, Grønbæk H, Haug A, Hicks RJ, Lenzo NP, Navalkissoor S, Nicolas GP, Pais B, Volteau M, Wild D, McEwan A, Lassmann M.
    Eur J Nucl Med Mol Imaging; 2024 Jul; 51(8):2428-2441. PubMed ID: 38528164
    [Abstract] [Full Text] [Related]

  • 27. Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist 177Lu-Satoreotide Tetraxetan.
    Reidy-Lagunes D, Pandit-Taskar N, O'Donoghue JA, Krebs S, Staton KD, Lyashchenko SK, Lewis JS, Raj N, Gönen M, Lohrmann C, Bodei L, Weber WA.
    Clin Cancer Res; 2019 Dec 01; 25(23):6939-6947. PubMed ID: 31439583
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Preliminary evaluation of (177)Lu-labeled knottin peptides for integrin receptor-targeted radionuclide therapy.
    Jiang L, Miao Z, Kimura RH, Liu H, Cochran JR, Culter CS, Bao A, Li P, Cheng Z.
    Eur J Nucl Med Mol Imaging; 2011 Apr 01; 38(4):613-22. PubMed ID: 21153409
    [Abstract] [Full Text] [Related]

  • 33. 177Lu-labeled RGD-BBN heterodimeric peptide for targeting prostate carcinoma.
    Jiang L, Miao Z, Liu H, Ren G, Bao A, Cutler CS, Shi H, Cheng Z.
    Nucl Med Commun; 2013 Sep 01; 34(9):909-14. PubMed ID: 23708872
    [Abstract] [Full Text] [Related]

  • 34. [177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy.
    de Jong M, Breeman WA, Bernard BF, Bakker WH, Schaar M, van Gameren A, Bugaj JE, Erion J, Schmidt M, Srinivasan A, Krenning EP.
    Int J Cancer; 2001 Jun 01; 92(5):628-33. PubMed ID: 11340564
    [Abstract] [Full Text] [Related]

  • 35. Preclinical pharmacokinetics, biodistribution, radiation dosimetry and toxicity studies required for regulatory approval of a phase I clinical trial with (111)In-CP04 in medullary thyroid carcinoma patients.
    Maina T, Konijnenberg MW, KolencPeitl P, Garnuszek P, Nock BA, Kaloudi A, Kroselj M, Zaletel K, Maecke H, Mansi R, Erba P, von Guggenberg E, Hubalewska-Dydejczyk A, Mikolajczak R, Decristoforo C.
    Eur J Pharm Sci; 2016 Aug 25; 91():236-42. PubMed ID: 27185299
    [Abstract] [Full Text] [Related]

  • 36. Preclinical pharmacokinetic, biodistribution, imaging and therapeutic efficacy of (177)Lu-Labeled glycated bombesin analogue for gastrin-releasing peptide receptor-positive prostate tumor targeting.
    Lim JC, Cho EH, Kim JJ, Choi SM, Lee SY, Nam SS, Park UJ, Park SH.
    Nucl Med Biol; 2015 Mar 25; 42(3):234-41. PubMed ID: 25498002
    [Abstract] [Full Text] [Related]

  • 37. Predictive patient-specific dosimetry and individualized dosing of pretargeted radioimmunotherapy in patients with advanced colorectal cancer.
    Schoffelen R, Woliner-van der Weg W, Visser EP, Goldenberg DM, Sharkey RM, McBride WJ, Chang CH, Rossi EA, van der Graaf WT, Oyen WJ, Boerman OC.
    Eur J Nucl Med Mol Imaging; 2014 Aug 25; 41(8):1593-602. PubMed ID: 24643780
    [Abstract] [Full Text] [Related]

  • 38. Tracer level radiochemistry to clinical dose preparation of (177)Lu-labeled cyclic RGD peptide dimer.
    Chakraborty S, Sarma HD, Vimalnath KV, Pillai MR.
    Nucl Med Biol; 2013 Oct 25; 40(7):946-54. PubMed ID: 23850487
    [Abstract] [Full Text] [Related]

  • 39. Efficacy and safety of concomitant 177Lu-DOTATATE and low-dose capecitabine in advanced medullary thyroid carcinoma: a single-centre experience.
    Satapathy S, Mittal BR, Sood A, Verma R, Panda N.
    Nucl Med Commun; 2020 Jul 25; 41(7):629-635. PubMed ID: 32371670
    [Abstract] [Full Text] [Related]

  • 40. Effect of calculation method on kidney dosimetry in 177Lu-octreotate treatment.
    Heikkonen J, Mäenpää H, Hippeläinen E, Reijonen V, Tenhunen M.
    Acta Oncol; 2016 Jul 25; 55(9-10):1069-1076. PubMed ID: 27219529
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.